Royal Invitation for University of Leicester Spin-out Company
Women who have made a significant contribution to British industry recognised
The CEO of a University of Leicester spin-out company, Sarah Middleton, has been honoured with an invitation from the Queen to attend a Reception at Buckingham Palace on 14th February, together with 200 other women who are regarded as having made a significant contribution to British Industry.
The company, Haemostatix Ltd, founded in 2003, is a biopharmaceutical company based in the University’s Department of Cardiovascular Sciences. The Company’s lead product is HaemoPlaxÔ, a synthetic alternative for platelet transfusion, which is designed to be both safer and more cost effective than current therapeutic products.
Sarah Middleton declared she is
“delighted and honoured to be invited to this prestigious event”.
Professor Alison Goodall, co-founder and Chief Scientific Officer of Haemostatix, who is Professor of Thrombosis & Haemostasis at the University, commented:
“This invitation acknowledges the fantastic job that Sarah is doing in developing the company”.
This is the second award for Haemostatix, which was named ‘Start Up Business of the Year’ by Medilink East Midlands, the membership organisation which supports the development of healthcare companies in the region.
In December 2005 Haemostatix Ltd raised £3.1million pounds from a syndicate of investors, Quester, NESTA and Catapult the Regional Venture Capital Fund to develop HaemoPlaxÔ to the clinic. In October 2006, the Company was in receipt of a DTI grant for Research and Development to initiate the development of a second product.
Notes to Editors:
Further information is available from Sarah Middleton, CEO, Haemostatix Ltd, tel 0116 256 3041, email email@example.com